One of the quintessential blue chips of the ASX, CSL Limited (ASX: CSL) has had a rough time of it during the pandemic.
Lockdowns all over the world were a big problem for the biotherapies company, as it couldn’t derive its usual volume of plasma collections — particularly in the United States — to make as much product as usual.
CSL is the largest collector of human blood plasma in the world. It relies on hundreds of thousands of donors to produce its critical medicines, including vaccines against the flu and polio.
Just before the pandemic hit the ASX in March 2020, the CSL share price was as high as $336.40. That was in mid-February 2020. Then it came crashing down, along with pretty much every other ASX share, to an initial low of $270.88. Then came the struggle through the first two years of COVID-19, during which time CSL shares have been effectively rangebound between the mid-$200s and about $315.
Today, the CSL share price is $270.66, up 1.38% in today’s session so far. Year-to-date, it’s down 8.5%.
So, when is the time right to pounce on CSL shares?
Well, one broker — Citi — reckons it’s a buy right now. They have a $335 price target for the next 12 months.
As my Fool colleague James reported last week, “Citi highlights that the company’s shares are underperforming the market this year but appears optimistic this will change as plasma collections begin to recover and the acquisition of Vifor Pharma closes.”
Morgan Stanley looks further ahead
Analysts at Morgan Stanley reckon the CSL share price is heading in the direction of $400 by 2025.
According to reporting in The Australian, the broker says this will be driven by three factors. And all of them relate to CSL’s US$12.3 billion (A$17.2 billion) acquisition of Swiss biotech giant Vifor Pharma.
Morgan Stanley analysts estimate the deal is 8% earnings per share-accretive to CSL in FY23 “if the acquisition indeed proceeds”. (According to a CSL statement yesterday, everything is on track for the deal to be completed by June).
The note reportedly said, “Given CSL’s long track record of fundamentally outperforming peers, we believe the Vifor outlook could be very different in CSL management’s hands.”
The analysts expect “material EPS upside” due to three key factors.
- Higher revenues through CSL sales channels for Vifor drugs Veltassa, Korsuva/Kapruvia, and later Vadadusta
- A revenue boost from Vifor’s Injectafer through greater adoption of Patient Blood Management
- Developmental transplant franchise benefits from Vifor’s Fresenius Medical Care and Fresenius Kabi relationships
The note said CSL’s plasma collections have returned to pre-pandemic levels and its vaccine products are performing strongly.
What else is affecting the CSL share price?
Yesterday, CSL revealed it has priced US$4 billion of bonds in the US market, which will help pay for Vifor.
CSL’s Chief Financial Officer, Joy Linton said:
The strong support shown by investors towards our inaugural US dollar bond issue reflects positively on our track record of disciplined financial management, as well as confidence in our strategy to invest in our leading therapeutic capabilities and generate sustainable growth.
The post Why Morgan Stanley says the CSL share price can hit $400 by 2025 appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- Why Bellevue Gold, CSL, Endeavour, and Serko shares are pushing higher today
- CSL share price lifts amid US$4b debt raise
- Why has the CSL share price struggled in the past month?
- Should ASX investors buy the dip in the CSL share price?
- 2 blue chip ASX 200 shares analysts rate as buys this month
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen owns CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/PMsu2dZ
Leave a Reply